Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
重新利用布鲁顿酪氨酸激酶 (BTK) 抑制剂来逆转高级别浆液性卵巢癌 (HGSC) 的免疫抑制
基本信息
- 批准号:10512441
- 负责人:
- 金额:$ 8.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-07 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAftercareAgammaglobulinaemia tyrosine kinaseAnimalsAntitumor ResponseAscitesBiological AssayBiological MarkersCRISPR/Cas technologyCancer cell lineCell LineCellsClinicalClinical TrialsCoculture TechniquesCombined Modality TherapyCustomDataDown-RegulationFDA approvedFailureGene TargetingGeneticGenetically Engineered MouseGrowthHematologic NeoplasmsHumanImmuneImmunityImmunosuppressionImmunotherapyInnate Immune ResponseIonsKnock-outLeadLibrariesMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of ovaryMediatingModelingMolecular Mechanisms of ActionMonitorMouse Cell LineMutationNatural ImmunityNeoplasm MetastasisOperative Surgical ProceduresOrganoidsOutcomeOvarian Serous AdenocarcinomaPaclitaxelPathologyPatientsPeripheralPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPlatinumPre-Clinical ModelPrimary NeoplasmPrincipal InvestigatorProteinsRegulationResistanceRoleSerousSignal PathwaySignal TransductionSolid NeoplasmT-LymphocyteTestingTherapeuticTimeTranslatingTumor BurdenTumor ImmunityTumor SuppressionTumor-infiltrating immune cellsTyrosine Kinase InhibitorVascular Endothelial Growth FactorsWorkadaptive immunityassay developmentbasec-myc Genescancer immunotherapycancer therapycell typechemotherapydesigndrug sensitivitydrug testingexhaustionfunctional statusgenetic approachhigh throughput screeninghigh-throughput drug screeningimmune checkpoint blockadeimmune functionimplantationimprovedin vivoinnovationmalignant ascitesmouse modelneoplastic cellnew combination therapiesnew therapeutic targetnovelnovel therapeuticspreventscreeningsingle-cell RNA sequencingsmall moleculesmall molecule inhibitorsmall molecule therapeuticssuccesstranscriptome sequencingtumortumor growthtumor microenvironmenttumor progressiontumor-immune system interactions
项目摘要
Project Summary
Background: Patients with high grade ovarian serous carcinoma (HGSC) have limited therapeutic options
beyond surgery and chemotherapy. Metastatic HGSC has remained largely incurable and almost always
unresponsive to immunotherapies due to its extremely “cold” tumor microenvironment (TME). Success in curing
this devastating cancer will likely rely upon new therapies targeting the crucial drivers of immunosuppression in
the TME, yet to be determined.
Innovation: The all too common failure of drugs that are efficacious in pre-clinical models to translate to efficacy
in human malignancies requires the development of assays that mimic the tumor in its native setting of the TME.
This proposal helps bridge that gap by taking advantage of an all-human, high-throughput drug screen that
leverages for the first time the immunosuppressive features of HGSC malignant ascites. To repurpose small-
molecule drugs for novel therapy of HGSC, we designed a custom compound library containing 4, 292 small
molecules either FDA-approved or druggable with a known mechanism of action (MOA), screening of which has
identified 9 top targets including BTK inhibition. To date, BTK inhibitors have been approved as a treatment for
hematologic malignancies but have not been studied in many solid tumors including ovarian cancer (OvCa). The
proposal utilizes both novel syngeneic mouse models carrying the most frequent mutations in human OvCa and
a patient-derived organoid model as a faithful representation of the TME to determine the efficacy and MOA of
BTK inhibitors for HGSC therapy.
Hypothesis: BTK inhibitors can improve HGSC outcomes by simultaneous activation of anti-tumor immunity
and direct inhibition of tumor growth.
Specific Aims:
Aim 1: What is the role of BTK in HGSC tumor cells?
Aim 2: How does BTK inhibition activate HGSC intratumoral immune cells?
Aim 3: Do BTK inhibitors reduce tumor growth in vivo?
Impact: Success in this patient-focused, hypothesis-driven proposal will not only advance the current
understanding of key immunosuppressive mechanisms in HGSC, but also lead to discovery of novel therapeutic
small molecule targets and unique biomarkers. Additionally, our project may suggest new combinational
therapies of these novel targets with already marketed or in clinical trial drugs in the setting of HGSC. If
successful, our study will provide a novel treatment paradigm for HGSC immunotherapy.
项目摘要
背景:高级别卵巢浆液性癌(HGSC)的治疗选择有限
除了手术和化疗之外。转移性HGSC在很大程度上仍然是无法治愈的,而且几乎总是
对免疫疗法无反应,因为它的肿瘤微环境(TME)极其寒冷。治愈成功
这种毁灭性的癌症很可能依赖于针对免疫抑制的关键驱动因素的新疗法。
TME,尚未确定。
创新:在临床前模型中有效而无法转化为疗效的药物的常见失败
在人类恶性肿瘤中,需要开发模拟肿瘤在其天然TME环境中的分析方法。
这项提议通过利用全人类、高通量药物筛查来帮助弥合这一差距
首次利用HGSC恶性腹水的免疫抑制特征。为了改变小的-
针对HGSC治疗的新分子药物,我们设计了一个包含4,292个小分子化合物的文库
FDA批准的或可与已知作用机制(MOA)一起用药的分子,其筛选已
确定了包括BTK抑制在内的9个顶级靶点。到目前为止,BTK抑制剂已被批准用于治疗
恶性血液病,但在包括卵巢癌(OvCa)在内的许多实体肿瘤中尚未被研究。这个
Proposal利用了携带人类OvCa最频繁突变的新的同基因小鼠模型和
患者衍生的器官模型作为TME的真实代表,以确定TME的疗效和MOA
用于HGSC治疗的BTK抑制剂。
假设:BTK抑制剂可通过同时激活抗肿瘤免疫来改善HGSC的预后
和直接抑制肿瘤生长。
具体目标:
目的1:BTK在HGSC肿瘤细胞中的作用是什么?
目的2:BTK抑制如何激活HGSC瘤内免疫细胞?
目的3:BTK抑制剂是否能抑制体内肿瘤的生长?
影响:这项以患者为中心、假设驱动的提案的成功不仅将推动当前的
了解HGSC的关键免疫抑制机制,也有助于发现新的治疗方法
小分子靶标和独特的生物标志物。此外,我们的项目可能会提出新的组合
这些新靶点的治疗已经上市或在HGSC环境下的临床试验药物中。如果
本研究的成功将为HGSC的免疫治疗提供一种新的治疗模式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAURIE Hollis GLIMCHER其他文献
LAURIE Hollis GLIMCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAURIE Hollis GLIMCHER', 18)}}的其他基金
Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer
制定实施社会风险转诊的实用指南:关爱健康中心 (CHC) 与癌症实施科学中心之间的合作伙伴关系
- 批准号:
10822141 - 财政年份:2023
- 资助金额:
$ 8.9万 - 项目类别:
Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication
了解 EHR 集成遗传性癌症风险评估应用程序对患者与提供者沟通的影响
- 批准号:
10831167 - 财政年份:2023
- 资助金额:
$ 8.9万 - 项目类别:
Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction
真实世界分子靶向治疗登记处 (MaTTeR):利用定向电子病历 (EMR) 提取丰富 CCDI 数据的试点研究
- 批准号:
10878384 - 财政年份:2023
- 资助金额:
$ 8.9万 - 项目类别:
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
重新利用布鲁顿酪氨酸激酶 (BTK) 抑制剂来逆转高级别浆液性卵巢癌 (HGSC) 的免疫抑制
- 批准号:
10661823 - 财政年份:2022
- 资助金额:
$ 8.9万 - 项目类别:
Multi-faceted Roles of an Atypical Kinase RIOK2 in Erythropoiesis and Myelodyplastic Syndromes
非典型激酶 RIOK2 在红细胞生成和骨髓增生异常综合征中的多方面作用
- 批准号:
10046930 - 财政年份:2020
- 资助金额:
$ 8.9万 - 项目类别:
Schnurri-3 Inhibitors: specific inducers of adult bone formation
Schnurri-3 抑制剂:成人骨形成的特异性诱导剂
- 批准号:
8259713 - 财政年份:2011
- 资助金额:
$ 8.9万 - 项目类别:
Schnurri-3 Inhibitors: specific inducers of adult bone formation
Schnurri-3 抑制剂:成人骨形成的特异性诱导剂
- 批准号:
8139368 - 财政年份:2011
- 资助金额:
$ 8.9万 - 项目类别:
From Sugar to Fat: How Transcription Factor XBP1 Regulates Hepatic Lipogenesis
从糖到脂肪:转录因子 XBP1 如何调节肝脏脂肪生成
- 批准号:
8308665 - 财政年份:2010
- 资助金额:
$ 8.9万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 8.9万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 8.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 8.9万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 8.9万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 8.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 8.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 8.9万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 8.9万 - 项目类别: